1Barnett AH, Huisman H, Jones R, et al. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double- blind, placebo-controlled trial [ J ]. Lancet, 2013, 382: 1413- 1423.
2yon Eynatten M, Neubacher D, Stat D, et al. Safety and efficacy of linagliptin in combination with basal insulin: a pre-specified, pooled analysis in a vulnerable population of elderly patients ( age ≥70 years) with type 2 diabetes[J]. Endocr Rev,2012,33:17.
3Ritz E. Limitations and future treatment options in type 2 diabetes with renal impairment [ J]. Diabetes Care, 2011,34 Suppl 2: S330-334.
4McGill J, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo- controlled study[ J ]. Diabetes Care,2013,36:237-244.
5Maximilian von Eynatten, Yan Gong, Angela Emser, et al. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and eardiovaseular disease: a pooled analysis of six phase III clinical trials[J]. Cardio Diab,2013,12:60.
6MARLINA-T2DM: efficacy, safety & modification of albuminuria in type 2 diabetes subjects with renal disease with LINAgliptin [ EB/OL]. [ 2013-12-12 ]. http://cliniealtrials, gov/et2/show/ NCT017925189 term = MARLINA&rank = 1.
7Zeng Z, Choi DS, Mohan V, et al. Linagliptin is efficacious and well tolerated in Asian patients with inadequately controlled type 2 diabetes//Proceedings of the 72nd Scientific Sessions of the American Diabetes Association[ J]. Philadelphia, US,2012.
8Schernthaner G, Barnett AH, Emser A, et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus [ J ]. Diab Obes Metab ,2012 ,14 :470- 478.
9Johansen OE, Neubacher D, Seck T, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre- specified, prospective, and adjudicated recta-analysis of a phase 3 programme[J/OL]. Cardiovas Diab,2012,11:3 [2013-12-12]. http ://www. eardiab, corn/content/11/1/3.
同被引文献14
1Balaban YH, Korkusuz P,Simsek H,et al. Dipepti-dylpeptidase IV ( DDP IV ) in NASH patients [ J ].Ann Hepatol,2007,6(4) :242 - 250.
